Symbols / NVS Stock $145.47 -1.36% Novartis AG

Healthcare • Drug Manufacturers - General • Switzerland • NYQ
NVS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Dr. Vasant Narasimhan M.D.
Exch · Country NYQ · Switzerland
Market Cap 280.79B
Enterprise Value 301.92B
Income 13.98B
Sales 56.67B
FCF (ttm) 12.12B
Book/sh 24.18
Cash/sh 6.04
Employees 75,267
Insider 10d
IPO Nov 07, 1996
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 55.86%
P/E 20.32
Forward P/E 14.93
PEG 2.53
P/S 4.95
P/B 6.02
P/C
EV/EBITDA 12.86
EV/Sales 5.33
Quick Ratio 0.82
Current Ratio 1.12
Debt/Eq 76.17
LT Debt/Eq
EPS (ttm) 7.16
EPS next Y 9.74
EPS Growth -11.60%
Revenue Growth 2.20%
EPS Gr Q/Q -14.50%
Rev Gr Q/Q
Earnings (next) 2026-04-28
Earnings (prior) 2026-02-04
ROA 11.14%
ROE 30.81%
ROIC
Gross Margin 75.97%
Oper. Margin 27.81%
Profit Margin 24.67%
Shs Outstand 1.91B
Shs Float 1.82B
Insider Own 0.00%
Instit Own 7.09%
Short Float 0.30%
Short Ratio 3.47
Short Interest 5.79M
52W High 170.46
vs 52W High -14.66%
52W Low 104.93
vs 52W Low 38.64%
Beta 0.52
Impl. Vol. 0.20%
Rel Volume 0.54
Avg Volume 2.25M
Volume 1.23M
Target (mean) $153.26
Tgt Median $151.57
Tgt Low $123.00
Tgt High $180.00
# Analysts 10
Recom Hold
Prev Close $147.48
Price $145.47
Change -1.36%
About

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$145.47
Low
$123.00
High
$180.00
Mean
$153.27

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 main Morgan Stanley Overweight → Overweight $170
2026-01-06 up Barclays Underweight → Equal-Weight
2025-12-08 up JP Morgan Neutral → Overweight
2025-09-12 down Goldman Sachs Neutral → Sell $118
2025-02-13 down UBS Buy → Neutral
2024-11-19 down Erste Group Buy → Hold
2024-10-30 main BMO Capital Market Perform → Market Perform $120
2024-09-11 down B of A Securities Buy → Neutral $130
2024-09-05 down Goldman Sachs Buy → Neutral $121
2024-09-03 down Jefferies Buy → Hold
2024-07-02 main Jefferies Buy → Buy $123
2024-04-24 main BMO Capital Market Perform → Market Perform $116
2024-02-23 init BMO Capital — → Market Perform $114
2024-01-23 init Morgan Stanley — → Equal-Weight $114
2023-09-25 up Morgan Stanley Underweight → Equal-Weight
2022-05-09 down Wolfe Research Outperform → Peer Perform
2021-12-06 down Exane BNP Paribas Outperform → Neutral
2021-12-03 down Bryan Garnier Buy → Neutral
2021-09-20 down Deutsche Bank Hold → Sell
2021-03-10 down Argus Research Buy → Hold
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
56,674.00
+9.57%
51,722.00
+10.85%
46,660.00
+7.36%
43,461.00
Operating Revenue
54,532.00
+8.38%
50,317.00
+10.73%
45,440.00
+7.66%
42,206.00
Cost Of Revenue
13,699.00
+6.80%
12,827.00
+2.85%
12,472.00
+7.68%
11,582.00
Reconciled Cost Of Revenue
13,699.00
+6.80%
12,827.00
+2.85%
12,472.00
+7.68%
11,582.00
Gross Profit
42,975.00
+10.49%
38,895.00
+13.77%
34,188.00
+7.24%
31,879.00
Operating Expense
25,331.00
+4.02%
24,351.00
-0.28%
24,419.00
+2.03%
23,933.00
Research And Development
11,200.00
+11.75%
10,022.00
-11.86%
11,371.00
+23.98%
9,172.00
Selling General And Administration
13,248.00
+5.43%
12,566.00
+0.39%
12,517.00
+2.66%
12,193.00
Other Operating Expenses
883.00
-49.91%
1,763.00
+232.02%
531.00
-79.32%
2,568.00
Total Expenses
39,030.00
+4.98%
37,178.00
+0.78%
36,891.00
+3.87%
35,515.00
Operating Income
17,644.00
+21.31%
14,544.00
+48.88%
9,769.00
+22.94%
7,946.00
Total Operating Income As Reported
17,644.00
+21.31%
14,544.00
+48.88%
9,769.00
+22.94%
7,946.00
EBITDA
22,821.00
+10.17%
20,715.00
+13.48%
18,255.00
+24.34%
14,682.00
Normalized EBITDA
23,121.00
+10.65%
20,895.00
+13.14%
18,469.00
+24.24%
14,866.00
Reconciled Depreciation
5,325.00
-12.26%
6,069.00
-26.68%
8,277.00
+23.45%
6,705.00
EBIT
17,496.00
+19.46%
14,646.00
+46.78%
9,978.00
+25.08%
7,977.00
Total Unusual Items
-300.00
-66.67%
-180.00
+15.89%
-214.00
-16.30%
-184.00
Total Unusual Items Excluding Goodwill
-300.00
-66.67%
-180.00
+15.89%
-214.00
-16.30%
-184.00
Net Income
13,984.00
+17.11%
11,941.00
-19.59%
14,850.00
+113.52%
6,955.00
Pretax Income
16,352.00
+19.88%
13,640.00
+49.51%
9,123.00
+27.11%
7,177.00
Net Non Operating Interest Income Expense
-980.00
-42.86%
-686.00
-63.72%
-419.00
+27.00%
-574.00
Interest Expense Non Operating
1,144.00
+13.72%
1,006.00
+17.66%
855.00
+6.88%
800.00
Net Interest Income
-980.00
-42.86%
-686.00
-63.72%
-419.00
+27.00%
-574.00
Interest Expense
1,144.00
+13.72%
1,006.00
+17.66%
855.00
+6.88%
800.00
Interest Income Non Operating
373.00
-34.33%
568.00
-9.41%
627.00
+66.31%
377.00
Interest Income
373.00
-34.33%
568.00
-9.41%
627.00
+66.31%
377.00
Other Income Expense
-312.00
-43.12%
-218.00
+3.96%
-227.00
-16.41%
-195.00
Gain On Sale Of Security
-300.00
-66.67%
-180.00
+15.89%
-214.00
-16.30%
-184.00
Tax Provision
2,385.00
+40.21%
1,701.00
+208.71%
551.00
-51.15%
1,128.00
Tax Rate For Calcs
0.00
+16.96%
0.00
+107.85%
0.00
-61.78%
0.00
Tax Effect Of Unusual Items
-43.76
-94.93%
-22.45
-74.82%
-12.84
+55.55%
-28.89
Net Income Including Noncontrolling Interests
13,967.00
+16.99%
11,939.00
-19.62%
14,854.00
+113.57%
6,955.00
Net Income From Continuing Operation Net Minority Interest
13,984.00
+17.11%
11,941.00
+39.37%
8,568.00
+41.64%
6,049.00
Net Income From Continuing And Discontinued Operation
13,984.00
+17.11%
11,941.00
-19.59%
14,850.00
+113.52%
6,955.00
Net Income Continuous Operations
13,967.00
+16.99%
11,939.00
+39.28%
8,572.00
+41.71%
6,049.00
Net Income Discontinuous Operations
6,282.00
+593.38%
906.00
Minority Interests
17.00
+750.00%
2.00
+150.00%
-4.00
0.00
Normalized Income
14,240.24
+17.70%
12,098.55
+37.97%
8,769.16
+41.34%
6,204.11
Net Income Common Stockholders
13,984.00
+17.11%
11,941.00
-19.59%
14,850.00
+113.52%
6,955.00
Diluted EPS
7.15
+21.81%
5.87
-17.32%
7.10
+123.97%
3.17
Basic EPS
7.21
+21.79%
5.92
-17.20%
7.15
+124.14%
3.19
Basic Average Shares
1,939.00
-3.91%
2,018.00
-2.83%
2,076.79
-4.78%
2,181.00
Diluted Average Shares
1,955.00
-3.93%
2,035.00
-2.72%
2,092.00
-4.78%
2,197.00
Diluted NI Availto Com Stockholders
13,984.00
+17.11%
11,941.00
-19.59%
14,850.00
+113.52%
6,955.00
Earnings From Equity Interest
-12.00
+68.42%
-38.00
-192.31%
-13.00
-18.18%
-11.00
Total Other Finance Cost
209.00
-15.73%
248.00
+29.84%
191.00
+26.49%
151.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
110,949.00
+8.51%
102,246.00
+2.30%
99,945.00
-14.91%
117,453.00
Current Assets
30,460.00
+2.55%
29,704.00
-2.55%
30,481.00
-17.42%
36,910.00
Cash Cash Equivalents And Short Term Investments
11,533.00
-13.62%
13,351.00
-4.38%
13,962.00
-25.00%
18,615.00
Cash And Cash Equivalents
11,435.00
-0.21%
11,459.00
-14.44%
13,393.00
+78.17%
7,517.00
Cash Equivalents
8,856.00
-0.20%
8,874.00
-12.88%
10,186.00
+119.53%
4,640.00
Cash Financial
2,579.00
-0.23%
2,585.00
-19.40%
3,207.00
+11.47%
2,877.00
Other Short Term Investments
98.00
-94.82%
1,892.00
+232.51%
569.00
-94.87%
11,098.00
Receivables
10,934.00
+18.19%
9,251.00
-1.33%
9,376.00
-5.24%
9,894.00
Accounts Receivable
8,937.00
+20.40%
7,423.00
+4.45%
7,107.00
-11.89%
8,066.00
Gross Accounts Receivable
8,989.00
+20.16%
7,481.00
+4.51%
7,158.00
-11.93%
8,128.00
Allowance For Doubtful Accounts Receivable
-52.00
+10.34%
-58.00
-13.73%
-51.00
+17.74%
-62.00
Other Receivables
1,242.00
+2.05%
1,217.00
-7.59%
1,317.00
+31.57%
1,001.00
Taxes Receivable
755.00
+23.57%
611.00
-35.82%
952.00
+15.11%
827.00
Inventory
6,269.00
+9.54%
5,723.00
-3.21%
5,913.00
-17.59%
7,175.00
Raw Materials
975.00
+15.66%
843.00
-12.46%
963.00
+3.10%
934.00
Work In Process
3,964.00
+14.97%
3,448.00
-1.54%
3,502.00
-4.66%
3,673.00
Finished Goods
1,330.00
-7.12%
1,432.00
-1.10%
1,448.00
-43.61%
2,568.00
Prepaid Assets
1,153.00
+17.06%
985.00
+28.93%
764.00
-16.14%
911.00
Hedging Assets Current
57.00
-46.23%
106.00
-77.25%
466.00
+47.94%
315.00
Other Current Assets
514.00
+78.47%
288.00
2,739.00
Total Non Current Assets
80,489.00
+10.96%
72,542.00
+4.43%
69,464.00
-13.76%
80,543.00
Net PPE
12,352.00
+13.60%
10,873.00
-0.47%
10,924.00
-10.42%
12,195.00
Accumulated Depreciation
-12,726.00
-14.65%
-11,100.00
+6.56%
-11,879.00
+15.81%
-14,109.00
Properties
0.00
0.00
0.00
0.00
Land And Improvements
912.00
+7.55%
848.00
-4.29%
886.00
-7.32%
956.00
Buildings And Improvements
11,523.00
+12.11%
10,278.00
-5.67%
10,896.00
-10.25%
12,141.00
Machinery Furniture Equipment
10,602.00
+15.50%
9,179.00
-5.78%
9,742.00
-18.54%
11,959.00
Construction In Progress
1,863.00
+15.71%
1,610.00
+32.73%
1,213.00
+2.45%
1,184.00
Other Properties
178.00
+206.90%
58.00
-12.12%
66.00
+3.13%
64.00
Goodwill And Other Intangible Assets
54,978.00
+6.40%
51,671.00
+2.89%
50,220.00
-17.60%
60,945.00
Goodwill
25,567.00
+3.28%
24,756.00
+6.06%
23,341.00
-20.34%
29,301.00
Other Intangible Assets
29,411.00
+9.27%
26,915.00
+0.13%
26,879.00
-15.06%
31,644.00
Investments And Advances
1,091.00
-3.28%
1,128.00
-38.26%
1,827.00
+13.76%
1,606.00
Long Term Equity Investment
98.00
-17.65%
119.00
-41.95%
205.00
+43.36%
143.00
Other Investments
210.00
+10.53%
190.00
-32.38%
281.00
Non Current Accounts Receivable
1,355.00
+34.69%
1,006.00
+15.50%
871.00
+0.93%
863.00
Non Current Deferred Assets
5,979.00
+23.58%
4,838.00
+1.90%
4,748.00
+14.19%
4,158.00
Non Current Deferred Taxes Assets
5,438.00
+24.75%
4,359.00
+1.16%
4,309.00
+15.24%
3,739.00
Other Non Current Assets
509.00
+20.62%
422.00
+96.28%
215.00
+7.50%
200.00
Total Liabilities Net Minority Interest
64,400.00
+10.81%
58,120.00
+9.26%
53,195.00
-8.33%
58,030.00
Current Liabilities
27,278.00
-4.93%
28,692.00
+8.72%
26,390.00
-7.91%
28,656.00
Payables And Accrued Expenses
9,517.00
+6.15%
8,966.00
-11.59%
10,141.00
-9.46%
11,200.00
Payables
7,037.00
+3.53%
6,797.00
-16.65%
8,155.00
-11.91%
9,258.00
Accounts Payable
4,456.00
-2.54%
4,572.00
-7.19%
4,926.00
-4.28%
5,146.00
Other Payable
879.00
+7.20%
820.00
+10.36%
743.00
Current Accrued Expenses
2,480.00
+14.34%
2,169.00
+9.21%
1,986.00
+2.27%
1,942.00
Employee Benefits
2,564.00
+3.68%
2,473.00
-9.41%
2,730.00
+3.45%
2,639.00
Pensionand Other Post Retirement Benefit Plans Current
2,251.00
+3.21%
2,181.00
-17.76%
2,652.00
+3.76%
2,556.00
Total Tax Payable
2,581.00
+16.00%
2,225.00
-7.64%
2,409.00
-28.50%
3,369.00
Income Tax Payable
1,969.00
+23.14%
1,599.00
-15.53%
1,893.00
-25.27%
2,533.00
Current Debt And Capital Lease Obligation
5,784.00
-30.51%
8,324.00
+31.83%
6,314.00
+3.05%
6,127.00
Current Debt
5,521.00
-31.75%
8,089.00
+32.96%
6,084.00
+3.54%
5,876.00
Other Current Borrowings
794.00
-76.34%
3,356.00
+53.17%
2,191.00
-2.23%
2,241.00
Current Capital Lease Obligation
263.00
+11.91%
235.00
+2.17%
230.00
-8.37%
251.00
Current Deferred Liabilities
127.00
+29.59%
98.00
-20.33%
123.00
Current Deferred Revenue
127.00
+29.59%
98.00
-20.33%
123.00
Other Current Liabilities
296.00
-30.19%
424.00
+303.81%
105.00
-43.55%
186.00
Total Non Current Liabilities Net Minority Interest
37,122.00
+26.15%
29,428.00
+9.79%
26,805.00
-8.75%
29,374.00
Long Term Debt And Capital Lease Obligation
29,592.00
+29.03%
22,934.00
+14.48%
20,034.00
-8.02%
21,782.00
Long Term Debt
27,935.00
+30.75%
21,366.00
+15.89%
18,436.00
-8.93%
20,244.00
Long Term Capital Lease Obligation
1,657.00
+5.68%
1,568.00
-1.88%
1,598.00
+3.90%
1,538.00
Long Term Provisions
612.00
+9.09%
561.00
-6.50%
600.00
-12.92%
689.00
Defined Pension Benefit
4,225.00
+62.25%
2,604.00
+377.80%
545.00
+11.00%
491.00
Non Current Pension And Other Postretirement Benefit Plans
1,872.00
-0.53%
1,882.00
-13.83%
2,184.00
+4.75%
2,085.00
Non Current Deferred Liabilities
3,397.00
+40.43%
2,419.00
+7.61%
2,248.00
-16.31%
2,686.00
Non Current Deferred Taxes Liabilities
3,397.00
+40.43%
2,419.00
+7.61%
2,248.00
-16.31%
2,686.00
Other Non Current Liabilities
957.00
-8.07%
1,041.00
-12.74%
1,193.00
-24.40%
1,578.00
Stockholders Equity
46,130.00
+4.73%
44,046.00
-5.62%
46,667.00
-21.36%
59,342.00
Common Stock Equity
46,130.00
+4.73%
44,046.00
-5.62%
46,667.00
-21.36%
59,342.00
Capital Stock
766.00
-3.40%
793.00
-3.88%
825.00
-7.30%
890.00
Common Stock
766.00
-3.40%
793.00
-3.88%
825.00
-7.30%
890.00
Share Issued
2,112.42
-3.54%
2,189.93
-3.84%
2,277.48
-5.25%
2,403.72
Ordinary Shares Number
1,908.15
-3.39%
1,975.09
-3.37%
2,044.03
-3.57%
2,119.61
Treasury Shares Number
204.27
-4.92%
214.84
-7.97%
233.44
-17.83%
284.11
Retained Earnings
46,561.00
-6.22%
49,649.00
-21.86%
63,540.00
Gains Losses Not Affecting Retained Earnings
45,414.00
+4.87%
43,306.00
+1249.92%
-3,766.00
+24.62%
-4,996.00
Treasury Stock
50.00
-5.66%
53.00
+29.27%
41.00
-55.43%
92.00
Minority Interest
419.00
+423.75%
80.00
-3.61%
83.00
+2.47%
81.00
Other Equity Adjustments
-3,255.00
+13.57%
-3,766.00
+24.62%
-4,996.00
Total Equity Gross Minority Interest
46,549.00
+5.49%
44,126.00
-5.61%
46,750.00
-21.33%
59,423.00
Total Capitalization
74,065.00
+13.23%
65,412.00
+0.47%
65,103.00
-18.20%
79,586.00
Working Capital
3,182.00
+214.43%
1,012.00
-75.26%
4,091.00
-50.44%
8,254.00
Invested Capital
79,586.00
+8.28%
73,501.00
+3.25%
71,187.00
-16.70%
85,462.00
Total Debt
35,376.00
+13.17%
31,258.00
+18.64%
26,348.00
-5.59%
27,909.00
Capital Lease Obligations
1,920.00
+6.49%
1,803.00
-1.37%
1,828.00
+2.18%
1,789.00
Net Tangible Assets
-8,848.00
-16.04%
-7,625.00
-114.61%
-3,553.00
-121.65%
-1,603.00
Tangible Book Value
-8,848.00
-16.04%
-7,625.00
-114.61%
-3,553.00
-121.65%
-1,603.00
Available For Sale Securities
465.00
-5.30%
491.00
-55.96%
1,115.00
+28.90%
865.00
Commercial Paper
4,045.00
-1.12%
4,091.00
+25.15%
3,269.00
+17.93%
2,772.00
Current Provisions
9,430.00
+7.20%
8,797.00
+24.25%
7,080.00
-16.35%
8,464.00
Financial Assets Designatedas Fair Value Through Profitor Loss Total
528.00
+1.93%
518.00
+2.17%
507.00
-15.22%
598.00
Held To Maturity Securities
53.00
+82.76%
29.00
-21.62%
37.00
Interest Payable
201.00
+18.93%
169.00
+45.69%
116.00
+0.00%
116.00
Investmentin Financial Assets
993.00
-1.59%
1,009.00
-37.79%
1,622.00
+10.87%
1,463.00
Investmentsin Associatesat Cost
98.00
-17.65%
119.00
-41.95%
205.00
+43.36%
143.00
Line Of Credit
682.00
+6.23%
642.00
+2.88%
624.00
-27.69%
863.00
Non Current Note Receivables
102.00
-10.53%
114.00
+34.12%
85.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
19,144.00
+8.66%
17,619.00
+21.86%
14,458.00
+1.56%
14,236.00
Cash Flow From Continuing Operating Activities
19,144.00
+8.66%
17,619.00
+23.90%
14,220.00
+9.06%
13,039.00
Cash From Discontinued Operating Activities
238.00
-80.12%
1,197.00
Net Income From Continuing Operations
13,967.00
+16.99%
11,939.00
+39.28%
8,572.00
+41.71%
6,049.00
Depreciation Amortization Depletion
5,325.00
-12.26%
6,069.00
-26.68%
8,277.00
+23.45%
6,705.00
Depreciation
1,251.00
+5.30%
1,188.00
-6.38%
1,269.00
-22.81%
1,644.00
Amortization Cash Flow
4,074.00
-16.53%
4,881.00
-30.35%
7,008.00
+38.47%
5,061.00
Depreciation And Amortization
5,325.00
-12.26%
6,069.00
-26.68%
8,277.00
+23.45%
6,705.00
Amortization Of Intangibles
4,074.00
-16.53%
4,881.00
-30.35%
7,008.00
+38.47%
5,061.00
Other Non Cash Items
19.00
+103.73%
-510.00
+35.03%
-785.00
-26066.67%
-3.00
Stock Based Compensation
1,096.00
+4.98%
1,044.00
+20.69%
865.00
+9.36%
791.00
Provisionand Write Offof Assets
1,318.00
Deferred Tax
2,385.00
+40.21%
1,701.00
+208.71%
551.00
-51.15%
1,128.00
Deferred Income Tax
2,385.00
+40.21%
1,701.00
+208.71%
551.00
-51.15%
1,128.00
Operating Gains Losses
128.00
+455.56%
-36.00
+78.44%
-167.00
+43.77%
-297.00
Gain Loss On Sale Of PPE
116.00
+256.76%
-74.00
+58.89%
-180.00
+41.56%
-308.00
Change In Working Capital
-1,577.00
-123.37%
-706.00
-91.33%
-369.00
+53.64%
-796.00
Change In Receivables
-1,124.00
-20.73%
-931.00
+38.10%
-1,504.00
-278.84%
-397.00
Changes In Account Receivables
-1,124.00
-20.73%
-931.00
+38.10%
-1,504.00
-278.84%
-397.00
Change In Inventory
34.00
+115.11%
-225.00
+58.79%
-546.00
+2.50%
-560.00
Change In Payables And Accrued Expense
-273.00
-160.00%
-105.00
-121.92%
479.00
+364.64%
-181.00
Change In Payable
-273.00
-160.00%
-105.00
-121.92%
479.00
+364.64%
-181.00
Change In Account Payable
-273.00
-160.00%
-105.00
-121.92%
479.00
+364.64%
-181.00
Change In Other Current Assets
-461.00
+8.17%
-502.00
-301.60%
-125.00
-48.81%
-84.00
Change In Other Current Liabilities
247.00
-76.63%
1,057.00
-20.35%
1,327.00
+211.50%
426.00
Investing Cash Flow
-4,877.00
+35.09%
-7,513.00
-234.26%
5,596.00
+281.20%
1,468.00
Cash Flow From Continuing Investing Activities
-4,877.00
+35.09%
-7,513.00
-211.82%
6,719.00
+252.89%
1,904.00
Cash From Discontinued Investing Activities
-1,123.00
-157.57%
-436.00
Net PPE Purchase And Sale
-1,535.00
-19.92%
-1,280.00
-55.53%
-823.00
-8.58%
-758.00
Purchase Of PPE
-1,548.00
-13.32%
-1,366.00
-28.87%
-1,060.00
-15.72%
-916.00
Sale Of PPE
13.00
-84.88%
86.00
-63.71%
237.00
+50.00%
158.00
Capital Expenditure
-3,900.00
-2.25%
-3,814.00
-38.54%
-2,753.00
-22.96%
-2,239.00
Net Investment Purchase And Sale
1,874.00
+3435.85%
53.00
-99.51%
10,849.00
+131.82%
4,680.00
Purchase Of Investment
-303.00
+91.69%
-3,648.00
-388.35%
-747.00
+97.85%
-34,810.00
Sale Of Investment
2,177.00
-41.18%
3,701.00
-68.08%
11,596.00
-70.64%
39,490.00
Net Business Purchase And Sale
-3,004.00
+23.19%
-3,911.00
-9.92%
-3,558.00
-311.81%
-864.00
Purchase Of Business
-3,004.00
+25.24%
-4,018.00
-12.83%
-3,561.00
Net Intangibles Purchase And Sale
-2,188.00
+7.60%
-2,368.00
-1003.82%
262.00
+122.72%
-1,153.00
Purchase Of Intangibles
-2,352.00
+3.92%
-2,448.00
-44.60%
-1,693.00
-27.97%
-1,323.00
Net Other Investing Changes
-24.00
-242.86%
-7.00
+36.36%
-11.00
-1000.00%
-1.00
Financing Cash Flow
-14,867.00
-26.61%
-11,742.00
+17.76%
-14,278.00
+30.56%
-20,562.00
Cash Flow From Continuing Financing Activities
-14,867.00
-26.61%
-11,742.00
+33.15%
-17,564.00
+15.07%
-20,681.00
Net Issuance Payments Of Debt
2,430.00
-44.65%
4,390.00
+326.87%
-1,935.00
+25.15%
-2,585.00
Issuance Of Debt
6,098.00
-0.73%
6,143.00
+1025.09%
546.00
+116.67%
252.00
Repayment Of Debt
-3,673.00
-35.49%
-2,711.00
-9.27%
-2,481.00
+12.55%
-2,837.00
Long Term Debt Issuance
6,098.00
-0.73%
6,143.00
16.00
Long Term Debt Payments
-281.00
-7.25%
-262.00
-1.55%
-258.00
+1.53%
-262.00
Net Long Term Debt Issuance
5,817.00
-1.09%
5,881.00
+2379.46%
-258.00
+1.53%
-262.00
Short Term Debt Issuance
958.00
+75.46%
546.00
+116.67%
252.00
Short Term Debt Payments
-3,392.00
-38.51%
-2,449.00
-10.17%
-2,223.00
+13.67%
-2,575.00
Net Short Term Debt Issuance
-3,387.00
-127.16%
-1,491.00
+11.09%
-1,677.00
+27.81%
-2,323.00
Net Common Stock Issuance
-9,212.00
-10.57%
-8,331.00
+4.45%
-8,719.00
+18.15%
-10,652.00
Common Stock Payments
-9,212.00
-10.57%
-8,331.00
+4.45%
-8,719.00
+18.15%
-10,652.00
Common Stock Dividend Paid
-7,818.00
-2.54%
-7,624.00
-5.09%
-7,255.00
+3.34%
-7,506.00
Cash Dividends Paid
-7,818.00
-2.54%
-7,624.00
-5.09%
-7,255.00
+3.34%
-7,506.00
Repurchase Of Capital Stock
-9,212.00
-10.57%
-8,331.00
+4.45%
-8,719.00
+18.15%
-10,652.00
Proceeds From Stock Option Exercised
30.00
-80.39%
153.00
+53.00%
100.00
Net Other Financing Charges
-267.00
-50.85%
-177.00
-151.30%
345.00
+1007.89%
-38.00
Changes In Cash
-600.00
+63.33%
-1,636.00
-128.32%
5,776.00
+218.90%
-4,858.00
Effect Of Exchange Rate Changes
576.00
+293.29%
-298.00
-398.00%
100.00
+412.50%
-32.00
Beginning Cash Position
11,459.00
-14.44%
13,393.00
+78.17%
7,517.00
-39.41%
12,407.00
End Cash Position
11,435.00
-0.21%
11,459.00
-14.44%
13,393.00
+78.17%
7,517.00
Free Cash Flow
15,244.00
+10.42%
13,805.00
+17.94%
11,705.00
-2.43%
11,997.00
Amortization Of Securities
-50.00
-211.11%
45.00
-57.55%
106.00
-59.23%
260.00
Dividend Received CFO
1.00
+0.00%
1.00
-50.00%
2.00
+100.00%
1.00
Earnings Losses From Equity Investments
12.00
-68.42%
38.00
+192.31%
13.00
+18.18%
11.00
Interest Paid CFO
-981.00
-14.74%
-855.00
-13.85%
-751.00
-12.59%
-667.00
Interest Received CFO
310.00
-36.61%
489.00
-24.19%
645.00
+155.95%
252.00
Sale Of Business
107.00
+3466.67%
3.00
Sale Of Intangibles
164.00
+105.00%
80.00
-95.91%
1,955.00
+1050.00%
170.00
Taxes Refund Paid
-2,562.00
-13.46%
-2,258.00
+18.98%
-2,787.00
-63.75%
-1,702.00
Cash From Discontinued Financing Activities
3,286.00
+2661.34%
119.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category